What they say:
A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November 2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054], by Prof. Thistlethwaite PA, Li X and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Bacillus Calmette Guerin (BCG) vaccine-based therapy for pulmonary arterial hypertension: Repurposing tuberculosis vaccine into a pulmonary arterial hypertensive vaccine: BCG, a tuberculosis vaccine, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3
Significance of the study:
This study suggests, first the first time, Bacillus Calmette Guerin (BCG) vaccine-based therapy, with detailed mechanistic insights, for curing pulmonary arterial hypertension. BCG vaccine has been found to be useful in the treatment of tuberculosis, for more than 100 years, more recently in the treatment of autoimmune diabetes. However, the mechanism of action remains largely unknown
Tuberculosis BCG vaccine, by increasing the expression of its target gene, it may decrease the expression of Notch3 and its target gene Hes-5 (Fig.1). Thereby, it may inhibit and promote, respectively, proliferation and differentiation of smooth muscle cells. And, thereby, prevent pulmonary hypertension (Figure 1). Thus, BCG vaccine, either alone or in combination with other drugs,” may be used to treat/cure pulmonary arterial hypertension (Figure 2). Together, by vaccinating pulmonary hypertensive patients with BCG, one may prevent pulmonary arterial hypertension.
Figure 1. Mechanistic insights into how tuberculosis BCG vaccine functions as an anti-pulmonary arterial hypertensive vaccine. BCG vaccine may promote insulin sensitivity and protect against myocardial infarction, via up regulation of reprogramming protein Lin-28
Figure 2. Tuberculosis BCG vaccine may function as an anti-hyperglycemic agent through induction of Lin-28
Details of the research findings:
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Undisclosed mechanistic information: How BCG vaccine decreases the expression of Notch3 and its target gene
Amount: $500#
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
For purchase and payment details, you may reach us at info@genomediscovery.org
# Research cooperation
References:
Web: http://genomediscovery.org or http://newbioideas.com/
Citation: Boominathan, L., Bacillus Calmette Guerin (BCG) vaccine-based therapy for pulmonary arterial hypertension: Repurposing tuberculosis vaccine into a pulmonary arterial hypertensive vaccine: BCG, a tuberculosis vaccine, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 1/July/2018, 11.36 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite us, drop us a line at info@genomediscovery.org